Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


International Regulators Forum Adds To Ambitious Policy Agenda

This article was originally published in The Gray Sheet

Executive Summary

Meeting March 19-21 in France, the International Medical Device Regulators Forum announced a major new project on standalone device software and the upcoming release of several guidance documents for public comment.

You may also be interested in...

Volunteers Sought By FDA For IMDRF Submission Project

The program would evaluate whether a new system proposed by the International Medical Device Regulators Forum to harmonize device marketing submissions is compatible with the agency's current submission requirements.

FDA Expects Class III Device Imports From China

As Chinese companies take market share from multinationals in China in some high-risk implantable device categories, FDA's device representative in Beijing says the agency expects to see made-in-China class III devices enter the U.S. Chinese manufacturers, however, face a number of hurdles before this can become reality.

Single-Audit, UDI And Software International Harmonization Docs Finalized

The International Medical Device Regulators Forum issued four final guidance documents on an upcoming pilot that will allow companies to satisfy inspection requirements for four countries in one inspection, and separate documents on a global unique device identification program and standalone software.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts